Can medication management review reduce anticholinergic burden (ACB) in the elderly? Encouraging results from a theoretical model

International Psychogeriatrics

Volumn 25, Issue 9, 2013, Pages 1425-1431

  He, Zikai ^a   Ball, Patrick Anthony ^b  

^a CHARLES STURT UNIVERSITY   (Australia)

^b CHARLES DARWIN UNIVERSITY   (Australia)

Author keywords

ACB; anticholinergic agents; anticholinergics; cognitive burden; reduction

Indexed keywords

CODEINE PHOSPHATE; DOMPERIDONE; ONDANSETRON; PREGABALIN;

AGED; ANTICHOLINERGIC EFFECT; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; COGNITION; DAILY LIFE ACTIVITY; DELIRIUM; FRAIL ELDERLY; GERIATRIC PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MEDICATION THERAPY MANAGEMENT; NEUROPATHIC PAIN; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; REVIEW;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; AUSTRALIA; CHOLINERGIC ANTAGONISTS; COGNITION; COGNITION DISORDERS; COST OF ILLNESS; DRUG UTILIZATION REVIEW; FEMALE; FRAIL ELDERLY; HUMANS; INTERVENTION STUDIES; MALE; MEDICATION THERAPY MANAGEMENT; MODELS, THEORETICAL; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RESIDENTIAL FACILITIES;

EID: 84881065900     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610213000872     Document Type: Review

References (26)

1. Abe, S., Chiba, K., Cirincione, B., Grasela, T. H., Ito, K. and Suwa, T. (2009). Population pharmacokinetic analysis of linezolid in patients with infectious disease: Application to lower body weight and elderly patients. The Journal of Clinical Pharmacology, 49, 1071-1078
2. Agar, M., Currow, D., Plummer, J., Seidel, R., Carnahan, R. and Abernethy, A. (2009). Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliative Medicine, 23, 257-265
3. AMH. (2012). Australian Medicines Handbook 2012. Adelaide, Australia: Australian Medicines Handbook
4. Boustani, M., Campbell, N., Munger, S., Maidment, I. and Fox, C. (2008). Impact of anticholinergics on the aging brain: A review and practical application. Aging Health Aging Health, 4, 311-320
5. Carnahan, R M., Lund, B. C., Perry, P. J., Pollock, B. G. and Culp, K. R. (2006). The anticholinergic drug scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. The Journal of Clinical Pharmacology, 46, 1481-1486
6. Davis, D. H. J., Rockwood, M. R. H., Mitnitski, A. B. and Rockwood, K. (2011). Impairments in mobility and balance in relation to frailty. Archives of Gerontology and Geriatrics, 53, 79-83
7. Desborough, J. et al. (2011). Multi-professional clinical medication reviews in care homes for the elderly: Study protocol for a randomised controlled trial with cost effectiveness analysis. Trials, 12, 218-226
8. Fox, C. et al. (2011). Anticholinergic medication use and cognitive impairment in the older population: The medical research council cognitive function and ageing study. Journal of the American Geriatrics Society, 59, 1477-1483
9. Hori, K. et al. (2011). Influence of anticholinergic activity in serum on clinical symptoms of Alzheimers disease. Neuropsychobiology, 63, 147-153
10. Hutchison, L C. and O'Brien, C. E. (2007). Changes in pharmacokinetics and pharmacodynamics in the elderly patient. Journal of Pharmacy Practice, 20, 4-12
11. Krum, H. and Teerlink, J. R. (2011). Heart failure 2: Medical therapy for chronic heart failure. The Lancet, 378, 713-721
12. Kuluris, B. (2007). General Practice and State Mental Health Services, Barwon Health (ed.). Victoria, Australia: Barwon Health, Victorian Government
13. Maidment, I. D., Fox, C., Boustani, M. and Katona, C. (2012). Medication management - the missing link in dementia interventions. International Journal of Geriatric Psychiatry, 27, 439-442
14. MIMS Australia. (2012). MIMS Online [Online]. Available at: Http://ezproxy.csu.edu.au/login?url=http://dx.doi.org/5230001-2; last accessed 15 March 2012 (CMPMedica, Sydney, Australia)
15. Minton, J. A., Tofade, T. S. and Shah, S. A. (2009). Psychosis from anticholinergic medications administered at a smoking cessation clinic. Journal of Pharmacy Practice, 22, 489-493
16. Neurology Expert Group. (2010). Therapeutic Guidelines Complete. North Melbourne, Australia: Therapeutic Guidelines
17. Nishtala, P. S. et al. (2009). Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. The Journal of Clinical Pharmacology, 49, 1176-1184
18. Rockwood, K K. (2005). What would make a definition of frailty successful? Age and Ageing, 34, 432-434
19. Rockwood, K. and Mitnitski, A. (2007). Frailty in relation to the accumulation of deficits. The Journals of Gerontology, 62A, 722-727
20. Rockwood, K. K. and Mitnitski, A. A. (2011). Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clinics in Geriatric Medicine, 27, 17-26
21. Rockwood, K., Song, X. and Mitnitski, A. (2011). Changes in relative fitness and frailty across the adult lifespan: Evidence from the Canadian National Population Health Survey. CMAJ: Canadian Medical Association Journal, 183, E487-E494
22. Ronaldson, K. J., Fitzgerald, P. B., Taylor, A. J., Topliss, D. J. and McNeil, J. J. (2011). A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. The Australian and New Zealand Journal of Psychiatry, 45, 458-465
23. Sittironnarit, G. et al. (2011). Effects of anticholinergic drugs on cognitive function in older Australians: Results from the AIBL study. Dementia and Geriatric Cognitive Disorders, 31, 173-178
24. Spinewine, A., Schmader, K E., Barber, N. and Hughes, C. (2007). Prescribing in elderly people 1: Appropriate prescribing in elderly people: How well can it be measured and optimised? The Lancet, 370, 173-184
25. Tune, L., Carr, S., Hoag, E. and Cooper, T. (1992). Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium. The American Journal of Psychiatry, 149, 1393-1394
26. Wawruch, M. et al. (2012). The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients. Pharmacoepidemiology and Drug Safety, 21, 170-176